Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pfister

Showing results (401-410 of 754) with videos related to

Pageof 76
Sort By:
Acta Neuropathologica|April 5, 2019
Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1Christian Thomas, Friederike Knerlich-Lukoschus, Harald Reinhard, et al.
The Lancet. Oncology|July 6, 2017
From class waivers to precision medicine in paediatric oncologyAndrew D J Pearson, Stefan M Pfister, Andre Baruchel, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
The Journal of Pathology|September 1, 2020
Drivers underpinning the malignant transformation of giant cell tumour of boneMatthew W Fittall, Iben Lyskjaer, Peter Ellery, et al.
Acta Neuropathologica|August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatTill Milde, Susanne Kleber, Andrey Korshunov, et al.
Neuro-Oncology|November 23, 2017
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot studyElke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, et al.
The American Journal of Surgical Pathology|January 12, 2018
Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC SubgroupPascal D Johann, Susanne Bens, Florian Oyen, et al.
Acta Neuropathologica|March 11, 2015
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersAndrey Korshunov, Marina Ryzhova, Volker Hovestadt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastomaElke Pfaff, Marc Remke, Dominik Sturm, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2021
Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signatureChristian Koelsche, Jamal K Benhamida, Felix K F Kommoss, et al.
Pageof 76

Showing results (401-410 of 754) with videos related to

Sort By:
Pageof 76
Acta Neuropathologica|April 5, 2019
Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1Christian Thomas, Friederike Knerlich-Lukoschus, Harald Reinhard, et al.
The Lancet. Oncology|July 6, 2017
From class waivers to precision medicine in paediatric oncologyAndrew D J Pearson, Stefan M Pfister, Andre Baruchel, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
The Journal of Pathology|September 1, 2020
Drivers underpinning the malignant transformation of giant cell tumour of boneMatthew W Fittall, Iben Lyskjaer, Peter Ellery, et al.
Acta Neuropathologica|August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatTill Milde, Susanne Kleber, Andrey Korshunov, et al.
Neuro-Oncology|November 23, 2017
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot studyElke Pfaff, Tobias Kessler, Gnana Prakash Balasubramanian, et al.
The American Journal of Surgical Pathology|January 12, 2018
Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC SubgroupPascal D Johann, Susanne Bens, Florian Oyen, et al.
Acta Neuropathologica|March 11, 2015
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersAndrey Korshunov, Marina Ryzhova, Volker Hovestadt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastomaElke Pfaff, Marc Remke, Dominik Sturm, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2021
Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signatureChristian Koelsche, Jamal K Benhamida, Felix K F Kommoss, et al.
Pageof 76